---
title: "Beyond the Divestiture: How Specialization Defines 2026's Biopharma Winners"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301693020.md"
description: "Biopharma's strategic refocusing intensifies as Novartis' divestiture catalyzes sector-wide specialization. From gene editing breakthroughs to sustainable packaging adoption, companies are doubling down on core competencies while niche players secure partnerships and regulatory wins in 2026."
datetime: "2026-10-13T10:15:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301693020.md)
  - [en](https://longbridge.com/en/news/301693020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301693020.md)
generator: "portal-rs"
---

# Beyond the Divestiture: How Specialization Defines 2026's Biopharma Winners

Novartis (NVS.US) set the tone for strategic realignment in 2026 by completing its eye care divestiture, triggering a sector-wide pivot toward core therapeutic franchises. Prime Medicine (PMEC.US) demonstrated the power of focused innovation with positive in vivo gene editing data for rare diseases, while Phio Pharmaceuticals (PHIO.US) leveraged its mRNA platform through partnerships targeting vaccine development. The trend extends beyond biotech: Amcor (AMCR.US) captured attention with sustainable packaging solutions adopted by global consumer giants, and Xenetic Biosciences (XENE.US) secured FDA approval for its biosimilar candidate. Even niche players like Phosphagenics (PHOS.US) found traction through transdermal delivery collaborations. Meanwhile, Globia Biotech (GLIBA.US) signaled consolidation pressures through acquisition talks, and municipal bond ETF Blackrock Municipal Income Trust (BHK.US) recalibrated portfolios amid shifting rate expectations. JPMorgan Emerging Markets Debt Fund (JEM.US) benefited from improving macro conditions, while Ocean Power Technologies (OPTT.US) advanced wave energy contracts with government backing—proving specialization remains the ultimate competitive moat.

### Related Stocks

- [PMEC.US](https://longbridge.com/en/quote/PMEC.US.md)
- [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md)
- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)
- [AMCR.US](https://longbridge.com/en/quote/AMCR.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [PHOS.US](https://longbridge.com/en/quote/PHOS.US.md)
- [GLIBA.US](https://longbridge.com/en/quote/GLIBA.US.md)
- [BHK.US](https://longbridge.com/en/quote/BHK.US.md)
- [JEM.US](https://longbridge.com/en/quote/JEM.US.md)
- [OPTT.US](https://longbridge.com/en/quote/OPTT.US.md)

## Related News & Research

- [NOVN: REMODEL success positions remibrutinib for a USD 4bn+ RMS opportunity](https://longbridge.com/en/news/302931949.md)
- [First Phosphate Files Q2 2026 Interim Results, Maintains Strong Cash Position](https://longbridge.com/en/news/302765445.md)
- [PMEC: HYTRON is being scaled through existing contracts to address rising labor costs](https://longbridge.com/en/news/302618526.md)
- [Novartis Remibrutinib Delivered Comprehensive Disease Control In Phase III RMS Trials](https://longbridge.com/en/news/302908183.md)
- [Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows](https://longbridge.com/en/news/302871273.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**